Bristol-Myers Squibb Company (BMY)
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
Bristol Myers Squibb (BMY) closed the most recent trading day at $54.62, moving 1.69% from the previous trading session.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)
Bristol Myers Squibb (BMY) has delivered a ~27% total return in three months, driven by topline growth and dividend strength. With the valuation rebound largely complete, BMY shifts from a high-conviction rerating to a balanced Hold, recommending disciplined profit-taking. Execution and regulatory risks remain around replacing Eliquis revenues, with CELMoDs and CAR-T progress critical to the long-term thesis.
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market, leveraging TRACTr technology for long-term oncology growth. Camzyos delivered 89% YoY revenue growth and promising phase 3 SCOUT-HCM results, supporting potential label expansion to adolescent oHCM patients.
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.
Top 10 Dividend Stocks For Uncertain Times
Stocks entered 2026 on a positive note before a global sell-off wiped out gains, driven by tariff tensions, a Greenland tug-of-war, and Japan's bond crisis. In this uncertain environment, dividends can offer security by providing steady income and downside resilience. Dividend safety requires looking beyond yield to factors such as reliability, growth, and consistency. SA Dividend Grades have demonstrated accuracy in avoiding cuts and delivering growth by analyzing key indicators, including payout ratio, leverage, and cash flow.
Final Trade: BMY, IGV, SOXX, GEN, AMZN
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $55.26, indicating a -2.4% shift from the previous trading day.
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
